Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Shares Issued (2016 - 2025)

Adma Biologics' Shares Issued history spans 12 years, with the latest figure at $430000.0 for Q4 2025.

  • For Q4 2025, Shares Issued fell 2.93% year-over-year to $430000.0; the TTM value through Dec 2025 reached $3.0 million, down 60.18%, while the annual FY2025 figure was $3.0 million, 60.18% down from the prior year.
  • Shares Issued reached $430000.0 in Q4 2025 per ADMA's latest filing, up from $389000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $53.8 million in Q4 2021 to a low of $8000.0 in Q4 2023.
  • Average Shares Issued over 5 years is $8.3 million, with a median of $548000.0 recorded in 2023.
  • Peak YoY movement for Shares Issued: surged 583883.77% in 2021, then tumbled 99.67% in 2022.
  • A 5-year view of Shares Issued shows it stood at $53.8 million in 2021, then crashed by 99.67% to $175000.0 in 2022, then plummeted by 95.43% to $8000.0 in 2023, then soared by 5437.5% to $443000.0 in 2024, then fell by 2.93% to $430000.0 in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Shares Issued are $430000.0 (Q4 2025), $389000.0 (Q3 2025), and $2.1 million (Q2 2025).